Antimicrobial Stewardship in Food Animals: Principles and Practical Application

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Antimicrobial stewardship in food animals is a coordinated effort to preserve drug efficacy while safeguarding animal and public health, necessitating accurate diagnosis, appropriate drug selection (narrowest spectrum agent), correct dosage and duration, outcome monitoring, and disease prevention.
• Resistance emerges via selection pressure from antimicrobial exposure, with young animals like preweaned calves identified as significant reservoirs for shedding resistant E. coli and Salmonella, underscoring the need to restrict antimicrobial use to confirmed bacterial infections.
• Critically important antimicrobial agents, including third/fourth-generation cephalosporins, fluoroquinolones, and macrolides, should be reserved for cases where culture and susceptibility testing confirm resistance to first-line drugs or where clinical presentation strongly indicates a pathogen uniquely susceptible to these agents.
• Stewardship programs must address behavioral dimensions influencing prescribing, such as farmer pressure and limited training, and require structured diagnostic sequences, including considering viral or parasitic etiologies before initiating antimicrobial therapy, especially for enteric disease in young animals.
• Effective stewardship involves establishing baseline antimicrobial use data, setting specific, measurable goals (e.g., reducing third-generation cephalosporin use in calves), prioritizing high-impact changes for common disease syndromes (e.g., calf diarrhea, bovine respiratory disease), and implementing a prudent use checklist for every prescription.
• Monitoring outcomes encompasses clinical effectiveness (treatment success, mortality), antimicrobial use volume (DDD/kg), and resistance indicators, with documentation of indication, drug, dose, duration, outcome, and withdrawal periods being crucial for regulatory compliance and practice audits.

Antimicrobial stewardship in food animal practice is the coordinated effort to preserve the efficacy of antimicrobial drugs while safeguarding animal health, public health, and food safety. This article provides a clinical framework for veterinarians working with cattle, swine, poultry, and other production species. It addresses the scientific rationale for stewardship, regulatory structures that shape prescribing, and practical strategies for implementing stewardship programs in ambulatory and production medicine settings.

The reader is assumed to be a practicing veterinarian who understands clinical pharmacology and production medicine. The article does not cover small animal practice, and it does not provide individualised patient protocols. Where specific drug choices or withdrawal periods are clinically relevant, current formulary and label references must be consulted, as regional approvals and residue tolerances vary.

The central clinical question is straightforward: how does a food animal veterinarian decide when an antimicrobial is necessary, which agent to select, and how to monitor the outcome, given the competing pressures of animal welfare, client expectations, regulatory obligation, and public health concern over resistance? The sections that follow build the conceptual foundation for those decisions, then move to practical application in later parts of this reference.

At a Glance

The Scientific Basis for Stewardship

Antimicrobial resistance arises through selection pressure exerted by antimicrobial exposure. When a bacterial population is exposed to a drug, susceptible organizms are suppressed and resistant subpopulations expand. This process operates in individual animals and at the population level within herds, flocks, and the broader environment. Food animals can carry resistant organizms without showing clinical disease, and young animals in particular may shed resistant bacteria at high levels. A systematic review of dairy calf studies found that preweaned calves were more likely than other animal groups on the farm to shed resistant fecal Escherichia coli and Salmonella enterica, and that antimicrobial treatment and feeding of antimicrobial-containing milk replacer were associated with increased resistance prevalence, though the evidence for those associations was less consistent across studies (Springer et al., systematic review of antimicrobial resistance in dairy calves).

The relevance of this reservoir to human health is debated, but the precautionary principle underpins most regulatory policy. Resistance genes can transfer between bacterial species, and foodborne pathogens of animal origin can carry clinically important resistance determinants. Stewardship therefore operates on two levels: reducing unnecessary antimicrobial exposure at the individual animal level, and reducing the total selective pressure exerted by a production system.

Defining Stewardship in Veterinary Contexts

Antimicrobial stewardship is often described as a set of principles instead of a single protocol. The World Organization for Animal Health publishes international standards for the prudent use of antimicrobials in the terrestrial animal health code, which many national programs reference when developing their own rules (WOAH terrestrial animal health standards). Professional veterinary organizations in several countries have issued complementary guidance on judicious use, including recommendations on diagnosis before treatment, use of narrow-spectrum agents, and avoidance of medically important drugs for growth promotion or routine prophylaxis (AVMA antimicrobial use and stewardship resources).

A practical definition of stewardship in food animal practice includes five elements: accurate diagnosis, appropriate drug selection, correct dose and duration, monitoring of outcomes, and prevention of disease so that antimicrobials become unnecessary. Each element requires specific skills and carries specific failure modes.

The One Health Rationale

Stewardship in food animals cannot be separated from human medicine. The same drug classes are used in both fields, and resistance that emerges in animal populations can compromise human treatment options. International expert networks have developed structured checklists for linking antimicrobial use surveillance, resistance surveillance, and stewardship activities across human and animal sectors. The JPIAMR ARCH and COMBACTE-MAGNET EPI-Net networks, through a Delphi consensus process involving experts from 18 countries, identified essential actions for veterinary settings, including the establishment of stewardship teams, government-supported programs, and specific requirements for the production, collection, and communication of antimicrobial use and resistance data (Compari et al., white paper on animal sector stewardship).

The same networks have published parallel guidance for hospital and outpatient human settings, which is relevant to food animal veterinarians mainly because it illustrates the shared structure of stewardship problems across sectors. Surveillance data are only useful when they are linked to action, and the absence of such linkage is a common failure mode in both human and veterinary medicine.

Regulatory Frameworks and Prescribing Authority

Veterinarians prescribe antimicrobials for food animals under regulatory systems that vary substantially by country. In the United States, the Food and Drug Administration Center for Veterinary Medicine oversees drug approval, labeling, extralabel use policy, and adverse event reporting (FDA Center for Veterinary Medicine animal drug information). In the European Union, the Veterinary Medicinal Products Regulation imposes additional restrictions on the prophylactic use of antimicrobials and requires collection of sales data by species. Australia uses a different classification system, with antimicrobials rated by importance to human health, and a survey of Australian veterinarians found that only 49% of respondents had heard of the national rating system and 22% used a traffic light system in practice (Sri et al., attitudes toward high-importance antimicrobials).

These differences matter clinically. A drug that is a first-line choice in one country may be a restricted agent in another. Veterinarians must know the classification system in their own jurisdiction and the specific conditions under which high-importance drugs can be prescribed. The practical consequence is that stewardship decisions are always made within a regulatory context, and the same clinical case may be managed differently in different regions.

Behavioral Dimensions of Prescribing

Stewardship is not purely a pharmacological problem. Veterinarian behavior is shaped by capability, opportunity, and motivation, a framework formalised in the COM-B model of behavior change. Qualitative research with Irish dairy veterinarians identified several barriers to responsible prescribing, including limited training in farmer behavior change, difficulties with laboratory testing, pressure from farmers to prescribe antimicrobials, concern for animal welfare, and the risk that farmers would seek prescriptions elsewhere (Farrell et al., COM-B analysis of veterinarian prescribing behavior). Facilitators included good knowledge of antimicrobial resistance, peer support, potential cost savings for farmers, and acceptance of shared responsibility for resistance.

These findings have direct practical implications. A stewardship program that only provides guidelines will fail if it does not address the social and economic pressures on prescribing decisions. Conversely, a program that builds peer networks and provides communication training may succeed even where drug availability is not the limiting factor.

Building the Stewardship Plan: Assessment and Goal Setting

A stewardship plan begins with an honest inventory of current prescribing. Review the previous 12 months of case records and group antimicrobial use by indication, drug class, and production stage. For dairy operations, separate calf, lactating cow, and dry cow treatments. For swine and poultry systems, distinguish water medication from individual injection and note whether treatments were metaphylactic, prophylactic, or therapeutic. This baseline serves as the reference point against which future progress is measured.

Set goals that are specific, measurable, and time-bound. A goal such as "reduce third-generation cephalosporin use in calves" is more useful than "use fewer antibiotics." Targets should reflect the operation's actual disease burden, not arbitrary percentages. The practical guidance from the JPIAMR ARCH and COMBACTE-MAGNET EPI-Net animal sector networks emphasizes that stewardship activities must be tailored to local conditions and linked to existing surveillance systems. A plan built around problems that do not exist on the farm will fail within months.

Prioritize the highest-impact changes first. In most food animal operations, the largest volume of antimicrobial use falls into a small number of disease syndromes. Calf diarrhea and respiratory disease, bovine respiratory disease in feedlot cattle, mastitis in lactating dairy cows, and respiratory and enteric disease in grow-finish swine account for the majority of prescriptions. Select one syndrome for the first improvement cycle. Document the current treatment protocol, the case definition used, and the outcomes measured.

The Diagnostic Sequence and Decision Points

The decision to administer an antimicrobial should follow a structured sequence. First, confirm that an infectious disease is present or highly probable. Second, determine whether the pathogen is likely bacterial. Third, assess whether the animal's immune status and the infection site allow a successful outcome. Fourth, select the narrowest drug that will reach the target tissue at effective concentrations. Fifth, define the criteria for stopping treatment.

Each step has specific failure modes. The most common error is treating viral respiratory disease with antimicrobials on the assumption that bacterial co-infection is inevitable. The second most common error is treating diarrhea in calves or piglets without assessing hydration status, since most enteric pathogens in these age groups are viral or parasitic and the primary intervention is fluid therapy. A systematic review of antimicrobial resistance in fecal Escherichia coli and Salmonella enterica from dairy calves found that preweaned calves carry higher levels of resistant fecal organizms than other animal groups on dairy farms, which argues for restricting antimicrobial use in this age class to cases where bacterial infection is confirmed or strongly supported by clinical findings.

Diagnostic testing changes the decision in specific circumstances. Collect a deep nasal swab or tracheal wash before starting treatment in a group outbreak of respiratory disease, particularly when mortality is rising despite treatment. Submit milk samples from clinical mastitis cases for culture before the first animal is treated when the herd has a recurring problem. Use fecal culture or PCR panels when calf diarrhea outbreaks persist beyond the expected duration or when Salmonella is suspected. The behavioral study of Irish dairy veterinarians identified issues with laboratory testing as a barrier to responsible prescribing, including delays in results and uncertainty about sample quality. Establish a working relationship with a diagnostic laboratory and agree on sample submission protocols before an outbreak occurs.

Selecting Antimicrobials: The Critically Important List and Decision Framework

The World Organization for Animal Health maintains terrestrial animal health standards that include a list of antimicrobial agents of veterinary importance. The highest priority agents are those that are essential for human medicine and have limited or no alternatives in veterinary medicine. These include third- and fourth-generation cephalosporins, fluoroquinolones, and macrolides. Use of these agents should be reserved for cases where culture and susceptibility testing confirm that no narrower alternative will be effective, or where the clinical presentation and herd history strongly support a pathogen that is predictably susceptible only to these drugs.

The attitudes of Australian veterinarians toward high-importance antimicrobials revealed that most practitioners supported restrictions on these drugs, but fewer than a quarter used a formal classification system in practice. Adopting a traffic light system within the clinic, where green drugs are first-line, amber drugs require justification, and red drugs require culture confirmation, provides a practical structure for daily decisions.

Monitoring Parameters and Documentation

Monitor three categories of outcomes: clinical effectiveness, antimicrobial use volume, and resistance indicators. Clinical effectiveness is measured by treatment success rates, mortality, relapse rates, and average duration of therapy. Antimicrobial use volume is tracked in defined daily doses per animal or per kilogram of production, or as total grams of active ingredient per production cycle. Resistance indicators require periodic culture and susceptibility testing of sentinel organizms, such as fecal E. coli from calves or respiratory pathogens from treatment failures.

Documentation must capture the clinical indication, the drug selected, the dose and route, the duration, the outcome, and any laboratory results that supported the decision. Record the withdrawal period applied and the date when the animal or group becomes eligible for slaughter or milk for human consumption. The FDA Center for Veterinary Medicine animal drug information provides the regulatory basis for label use and extralabel prescribing requirements, and current label references must be consulted for each drug before administration.

The Prudent Use Checklist

A practical checklist for each antimicrobial prescription in food animal practice:

• Is the diagnosis supported by clinical examination, laboratory findings, or both?
• Is a bacterial pathogen the most probable cause?
• Have non-antimicrobial interventions been addressed, including vaccination, nutrition, biosecurity, and environmental management?
• Has a first-line drug been considered before a critically important drug?
• Has culture and susceptibility testing been performed or submitted for cases involving critically important drugs?
• Is the dose, route, and duration consistent with the current label or a valid extralabel basis?
• Has the withdrawal period been calculated and recorded?
• Has the treatment outcome been scheduled for review?
• Has the case been documented in a format that supports periodic audit?

The AVMA antimicrobial use and stewardship resources provide additional professional guidance on judicious use principles. Species and production system differences matter. Group water medication in poultry and swine cannot achieve individual dose precision, so injectable therapy is preferred for individual animals requiring treatment. Dairy cows with mastitis require consideration of milk withdrawal and the risk of contaminated milk entering the bulk tank. Feedlot cattle treated for respiratory disease are typically managed in groups, which shifts the decision from individual case management to pen-level outbreak response. Each production system requires an adapted checklist, but the core diagnostic logic remains unchanged.

Recognized Complications and Failure Modes

Stewardship programs in food animal practice fail through predictable mechanisms. The most common is the partial implementation trap, where documentation improves but prescribing behavior does not change. This occurs when the stewardship plan exists as a written policy without embedded decision support at the point of prescribing. Detection requires auditing prescriptions against the stated plan at regular intervals, also confirming that forms were completed.

A second failure mode is the diagnostic shortcut. When laboratory results are delayed or unavailable, clinicians may initiate broad-spectrum therapy and then continue it beyond the window where it remains justified. The corrective action is to pair every empirical prescription with a scheduled reassessment point, typically 48 to 72 hours after initiation, at which the clinician must either narrow therapy, confirm the diagnosis, or document why continuation is necessary. Without this forced pause, empirical therapy becomes default therapy.

The third recognized complication is the substitution problem. A practice restricts a high-importance antimicrobial, and prescribers respond by shifting to a different agent of equal or greater importance instead of addressing the underlying indication. This is detected through periodic review of antimicrobial use data by drug class, not by individual drug. If total use of critically important classes remains static while one specific drug declines, substitution has occurred.

A fourth failure mode involves the farm team. When herd owners or managers perceive stewardship as a restriction imposed by external regulators, they may seek prescriptions from multiple veterinary practices or through non-veterinary channels. This fragmentation undermines both surveillance and treatment outcomes. The veterinary behavior research from Irish dairy practice identifies farmer pressure and the threat of clients seeking prescriptions elsewhere as direct barriers to responsible prescribing. Early detection relies on maintaining a current list of all antimicrobial products supplied to each herd and reconciling this against expected use patterns.

Common Errors and Corrective Actions

Less experienced clinicians commonly mistake duration of therapy for a fixed property of the drug instead of a function of the clinical response. The correction is to define objective treatment endpoints at the time of first prescription, such as resolution of fever, return to feed intake, or normalization of respiratory rate, and to stop therapy when these endpoints are met.

A second error is treating colonisation as infection. Young dairy calves frequently carry antimicrobial-resistant fecal organizms without clinical disease, and this carriage is associated with management practices including antibiotic treatment and medicated milk replacer feeding instead of with individual clinical episodes. Prescribing for a positive culture result without compatible clinical signs constitutes a stewardship failure. The corrective action is to require that culture results be interpreted in the context of physical examination findings and, where available, inflammatory markers.

A third error is the reflexive use of combination therapy. Fixed combinations are rarely justified in food animal medicine, and their use complicates both withdrawal period calculations and adverse event attribution. The correction is to require a written justification for any combination regimen, specifying which organizm or clinical scenario demands the second agent.

A fourth error is neglecting to document the reason for drug selection. When records contain only the drug name and dose, retrospective review cannot distinguish thoughtful prescribing from habit. The corrective action is to require a one-line indication statement on every prescription record.

Limitations of Current Evidence

The evidence base for stewardship interventions in food animal practice remains uneven. Systematic review of antimicrobial resistance in dairy calves shows consistent associations between preweaning status and resistant fecal shedding, but the causal pathways linking specific management practices to resistance outcomes are less clearly established. This limits the precision with which any single intervention can be recommended.

Expert opinion diverges on several points. The first is the role of metaphylaxis in respiratory disease control. Some authorities support targeted metaphylaxis in high-risk receiving cattle, while others argue that the practice perpetuates resistance pressure with marginal welfare benefit. The second contested area is the acceptable threshold for use of highest-priority critically important antimicrobials. The Australian survey of veterinarian attitudes found that a majority of respondents supported restrictions on high-importance antimicrobials, but substantial disagreement remains about which clinical scenarios justify their use. The third area concerns the weight given to human health impact versus animal welfare in regulatory decisions. These differences are not resolvable with current data, and practitioners should expect guidance to evolve as surveillance systems mature.

Escalation and Referral

Referral or specialist consultation is warranted when a herd-level disease pattern persists despite apparently appropriate antimicrobial therapy, when mortality exceeds expected levels for the diagnosed condition, or when the same clinical syndrome recurs across successive production cycles. These patterns suggest an undiagnosed underlying cause, such as a viral pathogen, management failure, or environmental reservoir, that antimicrobial therapy cannot address.

Laboratory involvement is indicated before initiating therapy in cases where the cost of a wrong drug choice is high, where the animal is valuable, or where a zoonotic pathogen is suspected. Diagnostic laboratories also serve a stewardship function by providing susceptibility data that inform both individual treatment and herd-level formularies. The veterinary sector guidance from the JPIAMR networks identifies the development of veterinary-specific clinical breakpoints as a research priority, and clinicians should interpret susceptibility results with awareness that some breakpoints are derived from human data.

Regulatory reporting obligations vary by jurisdiction, but the general principle is that suspected adverse drug reactions, therapeutic failures that may indicate product quality problems, and detection of notifiable pathogens should be reported through the appropriate national system. The FDA Center for Veterinary Medicine provides reporting pathways for product-related concerns in the United States, and equivalent agencies exist in other regions. When in doubt about whether an event requires reporting, the safer course is to contact the relevant authority and ask.

Troubleshooting Table

Frequently Asked Questions

How do I justify antimicrobial choices to producers who focus primarily on cost?

Frame the discussion around treatment success and long-term economics instead of acquisition price. A failed first-line therapy incurs repeated drug costs, extended labor, delayed weight gain, and potential mortality. Reference the animal sector stewardship guidance from the JPIAMR ARCH and EPI-Net networks, which emphasizes that stewardship teams should tailor activities to local capacities while linking usage data to outcomes. Show the producer a written treatment protocol with defined re-evaluation points. When a broader-spectrum drug is genuinely indicated, document the clinical rationale and expected benefit. When it is not, state that plainly and offer the narrow-spectrum alternative with its evidence base. Producers respond to predictable decision rules and clear endpoints.

What should I do when diagnostic laboratory support is delayed or unavailable?

Treat the laboratory as an adjunct, not a prerequisite, for responsible prescribing. Collect and store appropriate samples before starting therapy so culture and susceptibility testing can still guide de-escalation or re-treatment. Use clinical severity scores and herd-level history to make a working diagnosis, then commit to a re-examination date. The COM-B analysis of dairy veterinarians identified laboratory turnaround as a practical barrier to responsible prescribing, but also found that peer advice and knowledge of resistance patterns supported better decisions. If susceptibility results arrive after clinical resolution, record them for future herd-level treatment protocols. When sampling is impossible, choose the narrowest agent that covers the most likely pathogens based on local resistance data.

How does stewardship differ between group treatment and individual animal treatment?

Group treatment, common in poultry and swine, requires a population-level decision framework. Define the treatment trigger, the expected morbidity or mortality threshold, and the duration before reassessment. Individual treatment in cattle or small ruminants allows closer monitoring and earlier de-escalation. The systematic review of dairy calf resistance found that preweaned calves carry higher levels of resistant fecal organizms than other animal groups, which argues for stricter treatment thresholds in that age class. For group therapy, batch-level records of drug, dose, duration, and response are essential. For individual therapy, the same data belong in the patient record. Both approaches require the same question: will this antimicrobial change the outcome, and how will we verify that it did?

What records should I keep to demonstrate responsible stewardship?

Maintain a treatment log that captures the signalment, working diagnosis, drug, dose, route, duration, and outcome for every antimicrobial course. Add the reason the drug was selected, including any laboratory results, and note the re-examination findings. The animal sector white paper from the ARCH and EPI-Net networks lists the production, collection, and communication of antimicrobial usage data as essential actions for veterinary stewardship programs. Review these records quarterly to identify patterns: repeated use of the same drug class, prolonged courses, or treatments without documented response. Aggregate the data by production group and compare against the previous year. These records also support residue avoidance and provide defensible documentation if prescribing decisions are questioned.

How should I respond when a producer requests antimicrobials for a viral or self-limiting condition?

Decline the prescription and explain the distinction between supportive care and antimicrobial therapy. Offer a written protocol for the condition that includes fluid therapy, anti-inflammatory drugs where appropriate, and defined monitoring parameters. The AVMA antimicrobial use resources frame judicious use as selecting the right drug for the right diagnosis at the right dose and duration. If the producer insists, explore the underlying concern: fear of secondary bacterial infection, previous losses, or pressure from other advisors. Address that concern directly. Where secondary infection is a genuine risk, define the clinical signs that would trigger antimicrobial therapy and document that threshold in the herd health plan. This converts a refusal into a management decision with clear criteria.

How do I handle antimicrobial stewardship when I am covering a practice or region with different regulatory expectations?

Identify the local regulatory framework before prescribing. The FDA Center for Veterinary Medicine provides approved drug information and extralabel use policy for the United States, while the WOAH terrestrial animal health code sets international standards that many countries adopt or adapt. When covering unfamiliar territory, ask the practice for its treatment protocols and formulary, and check whether a veterinary-client-patient relationship is already established. If the regulatory structure differs from your home jurisdiction, consult the local authority or a colleague familiar with the region. Record the basis for any prescribing decision that falls outside your usual practice, and flag it for follow-up with the regular veterinarian.

Related Clinical & Scientific Guides

• Veterinary Formulary Essentials: Navigating Drug References
• Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy
• Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review

References and Further Reading

• Antimicrobial Resistance in Fecal Escherichia coli and Salmonella enterica from Dairy Calves: A Systematic Review.. 2019.
• White Paper: Bridging the gap between human and animal surveillance data, antibiotic policy and stewardship in the hospital sector-practical guidance from the JPIAMR ARCH and COMBACTE-MAGNET EPI-Net networks.. 2020.
• White Paper: Bridging the gap between surveillance data and antimicrobial stewardship in the outpatient sector-practical guidance from the JPIAMR ARCH and COMBACTE-MAGNET EPI-Net networks.. 2020.
• Exploring veterinarians' behavior relating to antibiotic use stewardship on Irish dairy farms using the COM-B model of behavior change.. 2023.
• White Paper: Bridging the gap between surveillance data and antimicrobial stewardship in the animal sector-practical guidance from the JPIAMR ARCH and COMBACTE-MAGNET EPI-Net networks.. 2020.
• Attitudes towards Use of High-Importance Antimicrobials-A Cross-Sectional Study of Australian Veterinarians.. 2022.
• FDA Center for Veterinary Medicine: Animal Drug Information. FDA CVM.
• AVMA Antimicrobial Use and Stewardship. American Veterinary Medical Association.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.

Related Articles

• Antimicrobial Stewardship in Food Animals: Withdrawal Times and Residue Avoidance
• Antimicrobial Stewardship in Equine Practice: Challenges and Solutions
• Antimicrobial Stewardship in Respiratory Infections of Dogs and Cats
• Antimicrobial Stewardship in Small Animal Practice: Implementing a Program
• Antimicrobial Stewardship in Canine Diarrhea: When Antibiotics Are Not the Answer

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.